You have 9 free searches left this month | for more free features.

ibrutinib

Showing 1 - 25 of 220

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma Trial (Ibrutinib, Venetoclax)

Not yet recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Small Lymphocytic Lymphoma
  • (no location specified)
Jul 19, 2023

Non-hodgkin Lymphoma Trial (Methotrexate, Rituximab (where available), Ibrutinib)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • (no location specified)
Aug 11, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Nemtabrutinib, Ibrutinib, Acalabrutinib)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • (no location specified)
Nov 22, 2023

Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)

Not yet recruiting
  • Mantle Cell Lymphoma Refractory
  • Ibrutinib
  • +3 more
  • (no location specified)
May 16, 2023

Glioblastoma Trial in Cleveland (Ibrutinib, Radiation, Temozolomide (TMZ))

Active, not recruiting
  • Glioblastoma
  • Ibrutinib
  • +2 more
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jan 30, 2023

Real World Data on Ibrutinib Use in PCNSL Rel/Ref

Recruiting
  • PCNSL
  • Ibrutinib
  • Milan, Italy
    Ospedale San Raffaele
Mar 13, 2023

Ependymoma, Medulloblastoma, Glioblastoma Trial in Augusta (Ibrutinib, Indoximod, Cyclophosphamide)

Recruiting
  • Ependymoma
  • +3 more
  • Ibrutinib
  • +3 more
  • Augusta, Georgia
    Augusta University, Georgia Cancer Center
Dec 16, 2022

Chronic GVHD Trial in Bethesda, Saint Louis (Ibrutinib)

Recruiting
  • Chronic GVHD
  • Ibrutinib
  • Bethesda, Maryland
  • +1 more
Jan 26, 2023

Malignant Tumors Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in

Active, not recruiting
  • Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
  • +2 more
  • Ibrutinib
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jan 20, 2023

Mantle Cell Lymphoma Trial in Houston (Ibrutinib)

Recruiting
  • Mantle Cell Lymphoma
  • Ibrutinib
  • Houston, Texas
    M D Anderson Cancer Center
Nov 1, 2022

Waldenstrom's Macroglobulinemia Trial in Boston (Ibrutinib)

Completed
  • Waldenstrom's Macroglobulinemia
  • Ibrutinib
  • Boston, Massachusetts
  • +1 more
Dec 5, 2022

CNS B-Cell Non-Hodgkin Lymphoma, Recurrent CNS Lymphoma, Refractory CNS Lymphoma Trial in Houston (Ibrutinib, Nivolumab)

Recruiting
  • Central Nervous System B-Cell Non-Hodgkin Lymphoma
  • +2 more
  • Ibrutinib
  • Nivolumab
  • Houston, Texas
    M D Anderson Cancer Center
Dec 13, 2022

Diffuse Large B-cell Lymphoma Trial in Tampa, Philadelphia (Tisagenlecleucel, Ibrutinib)

Terminated
  • Diffuse Large B-cell Lymphoma
  • Tisagenlecleucel
  • Ibrutinib
  • Tampa, Florida
  • +1 more
Jan 27, 2023

T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma Trial in New York, Columbus (Ibrutinib)

Active, not recruiting
  • T-cell Lymphoma
  • Relapsed and Refractory T-cell Lymphoma
  • Ibrutinib
  • New York, New York
  • +1 more
Nov 8, 2022

Graft Vs Host Disease Trial in Atlanta (Rituximab, Ibrutinib)

Recruiting
  • Graft Vs Host Disease
  • Atlanta, Georgia
    Northside Hospital
Oct 19, 2022

Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,

Active, not recruiting
  • Metastatic Melanoma
  • +6 more
  • Ibrutinib
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 13, 2023

Chronic Lymphocytic Leukemia Trial in Houston (Ibrutinib, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Ibrutinib
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022

Waldenstrom Macroglobulinemia Trial in China (Ibrutinib)

Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • Ibrutinib
  • Changchun, China
  • +5 more
Jan 27, 2023

CNS Lymphoma, Secondary CNS Lymphoma Trial run by the National Cancer Institute (NCI) (TEDD-R, TEDDI-R, Ibrutinib)

Recruiting
  • Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Ibrutinib
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Prostate Cancer Trial in San Francisco, Saint Louis (Ibrutinib, Blood samples for PSA and immune assays, Radical prostatectomy)

Recruiting
  • Prostate Cancer
  • Ibrutinib
  • +2 more
  • San Francisco, California
  • +1 more
Aug 15, 2022

Waldenstrom's Macroglobulinemia Trial in Boston (Ulocuplumab, Ibrutinib)

Active, not recruiting
  • Waldenstrom's Macroglobulinemia
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jun 20, 2022

Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,

Active, not recruiting
  • Prolymphocytic Leukemia
  • +2 more
  • Ibrutinib
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in New York (Ibrutinib, Pembrolizumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 22, 2022

Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)

Not yet recruiting
  • Lymphoma, Mantle-Cell
  • +7 more
  • (no location specified)
Jun 21, 2022